Alvotech Enrolls First Patient in Clinical Phase III Study Inv...
REYKJAVIK, Iceland, March 13, 2019 /PRNewswire-AsiaNet/ -- - Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA(R) high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors - 400 participants to be enrolled in Phase III study at...
Authors: LATEST ASIANET NEWS RELEASES